Clinical trials
Osteoarthritis, Knee trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
93 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 5 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 5 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 7 |
| 2022 | 7 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 50 |
| Unknown status | 23 |
| Recruiting | 8 |
| Active, not recruiting | 7 |
| Terminated | 3 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seoul National University Hospital | 10 |
| R-Bio | 5 |
| Yooyoung Pharmaceutical Co., Ltd. | 5 |
| Medipost Co Ltd. | 4 |
| PMG Pharm Co., Ltd | 4 |
| The Catholic University of Korea | 4 |
| Yonsei University | 4 |
| Chong Kun Dang Pharmaceutical | 3 |
| Gangnam Severance Hospital | 3 |
| L&C Bio | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Osteoarthritis, Knee | 93 |
| Osteoarthritis | 20 |
| Fractures, Stress | 2 |
| Osteoarthritis, Hip | 2 |
| Pain | 2 |
| Postoperative Nausea and Vomiting | 2 |
| Arthralgia | 1 |
| Arthritis, Rheumatoid | 1 |
| Chronic Pain | 1 |
| Femoral Fractures | 1 |
Trials
Showing 1 to 25 of 93. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.